» Articles » PMID: 34977507

Models for Non-alcoholic Fatty Liver Disease: Emerging Platforms and Their Applications

Overview
Journal iScience
Publisher Cell Press
Date 2022 Jan 3
PMID 34977507
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Non-alcoholic fatty liver disease (NAFLD) represents a global healthcare challenge, affecting 1 in 4 adults, and death rates are predicted to rise inexorably. The progressive form of NAFLD, non-alcoholic steatohepatitis (NASH), can lead to fibrosis, cirrhosis, and hepatocellular carcinoma. However, no medical treatments are licensed for NAFLD-NASH. Identifying efficacious therapies has been hindered by the complexity of disease pathogenesis, a paucity of predictive preclinical models and inadequate validation of pharmacological targets in humans. The development of clinically relevant models of the disease will pave the way to overcome these challenges. Currently, the combined application of emerging technologies (e.g., organ-on-a-chip/microphysiological systems) and control engineering approaches promises to unravel NAFLD biology and deliver tractable treatment candidates. In this review, we will describe advances in preclinical models for NAFLD-NASH, the recent introduction of novel technologies in this space, and their importance for drug discovery endeavors in the future.

Citing Articles

Hepatobiliary organoid research: the progress and applications.

Zou R, Dai Y, Liu F, Yang S, Hu H, Li F Front Pharmacol. 2025; 16:1473863.

PMID: 40008122 PMC: 11850396. DOI: 10.3389/fphar.2025.1473863.


Estrogen-dependent activation of TRX2 reverses oxidative stress and metabolic dysfunction associated with steatotic disease.

Smiriglia A, Lorito N, Bacci M, Subbiani A, Bonechi F, Comito G Cell Death Dis. 2025; 16(1):57.

PMID: 39890799 PMC: 11785963. DOI: 10.1038/s41419-025-07331-7.


Chemical Characterization and Differential Lipid-Modulating Effects of Selected Plant Extracts from Côa Valley (Portugal) in a Cell Model for Liver Steatosis.

Amorim R, Marques M, Melim C, Varela C, Sardao V, Teixeira J Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861102 PMC: 11768118. DOI: 10.3390/ph18010039.


Chemogenomic Screening in a Patient-Derived 3D Fatty Liver Disease Model Reveals the CHRM1-TRPM8 Axis as a Novel Module for Targeted Intervention.

Youhanna S, Kemas A, Wright S, Zhong Y, Klumpp B, Klein K Adv Sci (Weinh). 2024; 12(3):e2407572.

PMID: 39605182 PMC: 11744578. DOI: 10.1002/advs.202407572.


Molecular Insights into the Inhibition of Lipid Accumulation in Hepatocytes by Unique Extracts of Ashwagandha.

Li D, Han H, Sun Y, Zhang H, Yoshitomi R, Kaul S Int J Mol Sci. 2024; 25(22).

PMID: 39596320 PMC: 11594306. DOI: 10.3390/ijms252212256.


References
1.
Wilkening S, Stahl F, Bader A . Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties. Drug Metab Dispos. 2003; 31(8):1035-42. DOI: 10.1124/dmd.31.8.1035. View

2.
Poisson J, Lemoinne S, Boulanger C, Durand F, Moreau R, Valla D . Liver sinusoidal endothelial cells: Physiology and role in liver diseases. J Hepatol. 2016; 66(1):212-227. DOI: 10.1016/j.jhep.2016.07.009. View

3.
Underhill G, Khetani S . Bioengineered Liver Models for Drug Testing and Cell Differentiation Studies. Cell Mol Gastroenterol Hepatol. 2018; 5(3):426-439.e1. PMC: 5904032. DOI: 10.1016/j.jcmgh.2017.11.012. View

4.
Lee S, Sung J . Gut-liver on a chip toward an in vitro model of hepatic steatosis. Biotechnol Bioeng. 2018; 115(11):2817-2827. DOI: 10.1002/bit.26793. View

5.
Suurmond C, Lasli S, van den Dolder F, Ung A, Kim H, Bandaru P . In Vitro Human Liver Model of Nonalcoholic Steatohepatitis by Coculturing Hepatocytes, Endothelial Cells, and Kupffer Cells. Adv Healthc Mater. 2019; 8(24):e1901379. DOI: 10.1002/adhm.201901379. View